Want to join the conversation?
$BIIB expects R&D expense for 2016 to be approx. 19% to 20% of sales, including about $100MM earmarked for business development activity. The Company plans to continue to invest in a number of R&D programs across late-stage pipeline during 2016, including aducanumab for Alzheimer's disease and nusinersen for spinal muscular atrophy.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.